ClinicalTrials.gg
Status unknownNCT04157959Updated Nov 8, 2019

The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia

A Phase 1 interventional study of SHR4640 dose1 and Febuxostat dose2 in Hyperuricemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-11-08.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ruzinurad in Hyperuricemia — 1 open to participants now, 1 under way, none of them phase 3. ruzinurad · Hyperuricemia.

Planned enrollment
7th of 11
28 · median 34
Started
2019
the only one that year
Phase 1
8 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
10 of 11
Jiangsu HengRui Medicine Co., Ltd.

Among the 11 studies testing ruzinurad in Hyperuricemia, this one is the 7th largest by planned enrollment, is the only one that started in 2019, is one of 8 in phase 1, and was the 5th registered.

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

Browse Hyperuricemia studies →

Open to participants now

1 of the 11 studies testing ruzinurad in Hyperuricemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About ruzinurad

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing ruzinurad in Hyperuricemia, or all of them as a file.
02

Study summary

The objective of the study is to assess the pharmacodynamic properties of drug-drug of SHR4640 and Febuxostat interaction in patients with Hyperuricemia.

03

Conditions studied

  • Hyperuricemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has a ≥18 and ≤30 kg/m2;
  2. Screening sUA value ≥8mg/dl;
  3. Subject has no abnormalities in vital signs, , physical examination,imaging examination or safety laboratory values.

Exclusion criteria

Exclusion Criteria:

  1. Subject known or suspected of being sensitive to the study drugs or its ingredient;
  2. 、AST、>;
  3. History of kidney stones or screening kidney stones by B-ultrasound;
  4. History of ;
  5. History of xanthinuria;
  6. Donated blood(≥400ml)within 3 months prior to screening or received transfusion of blood。
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    SHR4640

    SHR4640 dose1 Oral Tablet Day1\~Day14 qd,Febuxostat dose2 Oral Tablet Day8 and Day14 qd.

    Drug: SHR4640 dose1 · Drug: Febuxostat dose2

  • Experimental
    Febuxostat

    Febuxostat dose2 Oral Tablet Day1 and Day14 qd, SHR4640 dose1 Oral Tablet Day8\~Day14 qd.

    Drug: SHR4640 dose1 · Drug: Febuxostat dose2

Interventions

  • Tablet,dose1,QD

  • DrugFebuxostat dose2

    Tablet,dose2,QD

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax) of SHR4640 and Febuxostat from plasma

    Time frame: Day1 to Day 14

  2. Area under the plasma concentration versus time curve (AUC) of SHR4640 and Febuxostat from plasma

    Time frame: Day1 to Day 14

Secondary outcomes

  1. Apparent terminal half-life (t1/2) of SHR4640 and Febuxostat from plasma

    Time frame: Day1 to Day 14

  2. Number of Participants With Adverse Events (AEs) and Serious Adverse Events

    Laboratory indicators, 12-lead electrocardiogram (ECG), physical examination,vital signs, adverse events (NCI-CTC AE 5.0), etc.

    Time frame: Clinical significant changes from Day-21 up to Day 29

07

Study locations

1 of 1 sites recruiting
  • The Affiliated Hospital of QingDao University
    Qingdao, Shan Dong, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Jun 2020, 7 months after the start.

Of 29 industry-sponsored phase 1 interventional studies under Hyperuricemia, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's planned 7 months is above that.

Counting every sponsor, half of 31 studies reached it within 6 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2019
First posted
Nov 8, 2019
StartActual
Oct 14, 2019
Primary completionEst.
Jun 1, 2020
CompletionEst.
Jun 30, 2020
Last update
Nov 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04157959
Responsible party
Sponsor
First posted
Nov 8, 2019
Start date
Oct 14, 2019
Primary completion
Jun 1, 2020 (estimated)
Completion
Jun 30, 2020 (estimated)
Last update
Nov 8, 2019

Study contacts

Cao Yu
Contact
Caoyu1767@126.com
0532-82911767

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruzinurad

Start the discussion